AHA Urges en Banc Review of 4th Circuit’s West Virginia 340B Contract Pharmacy Law Decision

Why It Matters

The ruling jeopardizes hospitals’ ability to secure discounted drugs for low‑income patients and could reshape 340B program enforcement across the United States.

Key Takeaways

• AHA seeks en banc review of 4th Circuit panel decision.
• Decision invalidated West Virginia law mandating 340B discounts for contract pharmacies.
• AHA claims ruling conflicts with 5th and 8th Circuits’ precedents.
• Hospitals fear loss of drug discounts for low‑income patients.

Pulse Analysis

The 340B Drug Pricing Program, created in 1992, allows eligible hospitals and clinics to purchase outpatient drugs at steep discounts, extending care to vulnerable populations. Many states, including West Virginia, have enacted statutes that require drug manufacturers to extend those discounts to contract pharmacies—independent outlets that dispense medication on behalf of covered entities. S.B. 325 was West Virginia’s effort to codify that requirement, but pharmaceutical companies, led by PhRMA, challenged the law, arguing it violated federal supremacy and the program’s statutory framework.

In March, a three‑judge panel of the 4th Circuit affirmed a district‑court injunction, effectively nullifying the state law. The AHA’s amicus brief contends that the panel’s reasoning departs from established legal principles, adopts an untested test, and ignores a robust record from the states. It also highlights inconsistency with rulings from the 5th and 8th Circuits, which have upheld similar statutes in Louisiana and Arkansas. By requesting an en banc rehearing, the AHA hopes to align the 4th Circuit with broader judicial consensus and protect the contractual mechanisms that enable hospitals to stretch limited resources.

The stakes extend beyond West Virginia. If the panel’s decision stands, hospitals nationwide could lose a critical avenue for accessing affordable medications, pressuring margins and potentially curtailing services for low‑income patients. An en banc reversal would reinforce state authority to supplement federal drug‑pricing rules, offering a clearer path for other jurisdictions to safeguard 340B discounts. Stakeholders—from health‑system executives to policymakers—are watching the case closely, as its outcome may set a pivotal precedent for the future of the 340B ecosystem.